0RA9.LSE Abivax S.A.

Healthcare Commercial Services & Supplies London Exchange
87.48 EUR
Close of Nov 3, 2026
60.70 139.00
Market cap
EUR 873M
P/E
-
P/B
-
ROE
-73.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 0RA9.LSE undervalued?

Graham number

The Graham number of Abivax S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Abivax S.A. fundamental analysis

No fundamental analysis for Abivax S.A. yet.

Abivax S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Abivax S.A.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in…

Full company profile